.tb-field[data-toolset-blocks-field="2d0c4e6a6b8a86460519f393047902c4"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="9ccf0efdddbc62a6b6fe15e9f2a6fde3"] { font-size: 13px;text-align: left;padding: 0px;margin: 0px; }  .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="c35d9a7279448f10d949ebc7e457ae45"] { text-align: left;justify-content: flex-start; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { background-color: rgba( 217, 217, 217, 0.13 );padding: 10px;margin-bottom: 15px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 );border: 1px solid rgba( 215, 213, 213, 1 );grid-template-columns: minmax(0, 0.665fr) minmax(0, 0.335fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-field[data-toolset-blocks-field="627e912eb953c8ed786ea0c7e10207ea"] { font-size: 14px;text-align: left;padding: 0px;margin: 0px; }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }   h1.tb-heading[data-toolset-blocks-heading="4273ccf7ca31e5697065fdb41a036bd2"]  { font-size: 26px; }  .wpv-custom-search-filter-submit[data-toolset-views-custom-search-submit="8ca7a9b3f80df5aa18fe74ad2a58d731"] { text-align: left; } @media only screen and (max-width: 781px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } @media only screen and (max-width: 599px) {   .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="9b43713f5e44ea2ee722edd53959cdd9"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } 

News and Press Releases

CARBOGEN AMCIS Shanghai Site achieves successful outcome in Unannounced NMPA GMP Inspection

China’s NMPA confirms robust GMP compliance at CARBOGEN AMCIS Shanghai, with no observations identified following a comprehensive unannounced inspection 6 May 2026 -- Bubendorf, Switzerland -- CARBOGEN AMCIS, a Switzerland-based...

Category: BioManufacturing, Clinical Trials, Other, Pharmaceutical
Posted: May 6, 2026

CARBOGEN AMCIS

info@carbogen-amcis.com

Hauptstrasse 171 CH-4416 Bubendorf Switzerland

Ofichem unifies brands under single CDMO and pharmaceutical supplier

One Ofichem. One voice. A more connected approach to pharmaceutical partnerships 8 April 2026 -- Ter Apel, the Netherlands -- Ofichem has brought its brands - Ofichem BV, Ofipharma, Ofimedicine,...

Category: Drug Delivery, Logistics, Manufacturing and Packing, Other
Posted: April 8, 2026

Ofichem

info@ofichem.com

Laboratorium Ofichem BV, Heembadweg 5, 9561 CZ Ter Apel The Netherlands

Samsung Biologics completes acquisition of GSK’s manufacturing facility in Rockville, Maryland

Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics’ geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support Plans...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: March 31, 2026

Samsung Biologics

300, Songdo bio-daero, Yeonsu-gu, Incheon, Republic of Korea

Lonza Launches Media Development Lab in Singapore for Cell Culture Media Optimisation

New media development services designed to optimize cell culture media development and identify robust, scalable media formulations driving cell culture performance and reliability The offering is designed to improve performance,...

Category: BioManufacturing, Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 26, 2026

Lonza

Muenchensteinerstrasse 38 Basel, 4002

Samsung Biologics Recognized for Advancing Sustainability at 2026 CDMO Leadership Awards

• Reinforcing long-term commitment to embedding sustainability across operations and partnerships• Continuing to support clients in delivering high-quality, life-saving medicines to patients worldwide. 16 March 2026 -- Incheon, South Korea...

Category: BioManufacturing, Other, Pharmaceutical
Posted: March 16, 2026

Samsung Biologics

300, Songdo bio-daero, Yeonsu-gu, Incheon, Republic of Korea

Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California

24 February 2026 -- California, US -- Avid Bioservices, Inc., a dedicated biologics CDMO, today announced the grand opening of its new Early Phase Center of Excellence, a state of...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: February 24, 2026

Avid Bioservices

14191 Myford Road Tustin, California 92780

Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia

Publication presents clinical findings highlighting evenamide’s glutamatergic modulation as a therapeutic strategy for patients with inadequate response or treatment-resistant schizophrenia (TRS) By targeting the hippocampus region of the brain, evenamide...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 3, 2026

Newron Pharmaceuticals

info@newron.com

via Antonio Meucci 3 20091 Bresso (Mi) Italy

Recipharm expands manufacturing to meet demanding FDA requirements

Established a new, dedicated non-bacterial beta-lactam manufacturing facility in response to FDA guidance Secured a strategic partnership with an innovative biopharma company seeking rapid regulatory compliance Developed a scalable platform...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 26, 2026

Recipharm

Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis

The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan (HRCT) imaging biomarkers as a co-primary endpoint 20 January...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 20, 2026

Brainomix

investors@brainomix.com

First Floor, Seacourt Tower West Way Oxford OX2 0JJ

Exciva raises €51 million ($59m) in Series B funding round co-led by Gimv and EQT

20 January 2026 -- Heidelberg, Germany -- Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59m)...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 20, 2026

Exciva

info@exciva.com

Hauptstrasse 25, 69117 Heidelberg, Germany

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Issued and pending claims expected to protect ALTO-207 into the mid-2040s 14 January 2026 -- California, US -- Alto Neuroscience, Inc, a clinical-stage biopharmaceutical company focused on the development of...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2026

Alto Neuroscience

info@altoneuroscience.com

650 Castro Street, Suite 450 Mountain View, CA 94041

Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045

New patent based on treatment of populations identified to be particularly responsive to ondansetron treatment after examination of Adial’s clinical data and information 14 January 2026 -- Virginia, US --...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2026

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent

EP4615820 – “Crystalline Forms of Evenamide” is expected to extend asset exclusivity in EU into 2044 Evenamide is currently being investigated in Newron’s global ENIGMA-TRS Phase III development program, enrolling...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 6, 2026

Newron Pharmaceuticals

info@newron.com

via Antonio Meucci 3 20091 Bresso (Mi) Italy

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis

5 January 2026 -- California and Massachusetts, US -- MapLight Therapeutics, Inc today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 5, 2026

MapLight Therapeutics

info@maplightrx.com

800 Chesapeake Drive, Redwood City, California 9406

GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026

GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Company to seek FDA alignment on global Phase 3 program replicating Phase 2b design Phase 3 initiation targeted...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 5, 2026